In the First Year of Release, Inscripta’s MAD7 CRISPR Enzyme is Widely Adopted by the Gene-Editing Community
Existing investors contribute an additional $30 million to accelerate tools that will revolutionize genomic research BOULDER, Colo., Dec. 19, 2018 /PRNewswire/ — Inscripta™, a leading gene-editing technology company, today announced that MAD7, its proprietary CRISPR enzyme, has achieved wide adoption by academic, commercial, and government researchers in its first year of availability. MAD7 was recently recognized […]